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tus, greater work-related impairments, and increased health care resource use.
Given the additional burden of this comorbidity, the management of dyspepsia
among patients with AF should be a greater area of focus.
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OBJECTIVES: To analyse the association between Health Related Quality of Life
(HRQoL) and age, in hypertensive patients and the correlation between HRQoL
reported by patients and evaluated by their doctors. METHODS: Observational,
cross-sectional, multi-centre study, in Primary and Specialised Care. Inclusion of
5,031 hypertensive patients, selected by quotes according to three age groups (65,
65-79,  80 years) was planned. Selection criteria were: patients whose age was
over 18, diagnosed as having hypertension at least one year before inclusion and
attended a follow-up visit. Information related to hypertension, basic socio-demo-
graphic and clinical data, the self-administered specific questionnaire MINICHAL
for the evaluation of HRQoL (higher scores indicative of lower HRQoL), and a visual
analogue scale (VAS) for the general evaluation of HRQoL (higher scores indicative
of higher HRQoL) by patients and doctors, were recorded. Data of 4,346 eligible
patients were included. HRQoL-age correlation was analysed by Spearman’s-rho,
differences among age groups by Kruskal-Wallis and patient/doctor agreement by
the intraclass correlation coefficient (ICC). RESULTS: Mean age (SD) was
68.35(12.60). 38.1% of patients were under 65, 36.9% between 65 and 80 and 25.0%
were over 80 years old. 54.5% were men. Mean time since diagnosis was 10.33(7.68)
years. 34.2% had a family history of high blood pressure. Mean scores in MINICHAL
were: State of Mind dimension 8.07(5.83), Somatic Manifestations dimension
3.24(3.06). Worsening of both dimensions was found when comparing groups of
higher age (p0.001) as well as significant moderate correlations of both dimen-
sions with age (0.335, p0.001; 0.397 p0.001). Mean(SD) VAS score for doctors’
evaluation was 66.84(15.82) and 63.93(18.46) that of patients; ICC for agreement was
0.697 (0.672, 0.687 and 0.663 by age groups). CONCLUSIONS: An impact of age on
HRQoL worsening is evidenced. Patient/doctor agreement in the evaluation of
HRQoL is adequate; however doctors trend to overestimate the HRQoL of patients.
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OBJECTIVES: To determine the health related quality of life (HRQOL) of patients
with heart failure (HF) hospitalized in the Canary Islands and to estimate their
utilities by analyzing the influence of sociodemographic and clinical factors such
as gender or severity according to New York Heart Association (NYHA) classifica-
tion. A secondary objective is to obtain utilities to be used in an economic model to
evaluate a cardiac device. METHODS: Descriptive analysis within a prospective
observational multicenter study of a cohort of patients with HF admitted to cardi-
ology or internal medicine units at several hospitals in the Canary Islands, Spain.
HRQOL was assessed using the EQ-5D questionnaire among others. Utility was
estimated for the entire sample and for subgroups of patients, using the Spanish
tariffs VAS (visual analog scale) and TTO (time trade-off). RESULTS:We present the
results of a sample of 176 patients enrolled so far (51% male, mean age 74 years).
Average utility (SD) of the entire sample is 0.5297 (0.2107) (VAS rate). Women re-
ported poorer HRQOL than men (0.5182 vs. 0.5421); HRQOL is lower in health states
of lower functional capacity: 0.6400 in patients with NYHA-I and 0.4491 in patients
with NYHA-III. CONCLUSIONS: Differences between sub-groups and overall low
HRQOL were observed, possibly due to the hospitalization of surveyed patients.
These local findings coincide with the international literature and may be useful
for developing the economic model.
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OBJECTIVES: To compare work productivity impairment between Russian patients
with those in the 5EU and US and assess whether conditions have similar impact
across these geographies.METHODS:The study included data from the 2011 Russia
(N10,039), US (N75,000), and 5EU (N 57,512) National Health and Wellness
Survey, a survey representative of urban adults in Russia and total adult popula-
tions of the US and each 5EU country. Respondents self-reported physician diag-
nosis of type 2 diabetes (T2D) and cardiovascular (CV) conditions, as well as their
height and weight used to calculate obesity (BMI30). Work productivity impair-
ment and impairment in non-work activities was assessed with the Work Produc-
tivity and Activity Impairment (WPAI) questionnaire. Two-way ANOVAs tested for
differences in work productivity impairment by geography and condition.
RESULTS: There were regional differences in mean health-related work impair-
ment, with Russia the highest (22.6%), followed by 5EU (19.4%) and US (14.9%;
p0.001). Collapsing across geographies, obesity, T2D, and CV conditions were
each associated with more impaired work productivity (all ps0.01), but the mag-
nitude of the decrement associated with each disease depended on region (all
ps0.01). The incremental work productivity loss associated with obesity was
smallest in Russia (1.5%), compared with 5EU (3.9%) and US (2.7%). T2D patients in
Russia and 5EU experienced similar incremental work productivity impairment
(8.5%), while US T2D patients showed a difference of 5.0%. Similarly, Russians with
CV conditions were more impaired than in 5EU and US when compared with
non-CV patients (8.1% vs. 7.1% and 4.4%, respectively). CONCLUSIONS: Russians
have greater health-related work impairment than adults in US and 5EU. The in-
cremental burden of obesity, T2D, and CV conditions in Russia appears to differ
from the US and 5EU, being relatively small for obesity but greater for T2D and CV
conditions. These differences highlight the importance of country-specific infor-
mation for these markets.
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Anticoagulants are recommended for stroke prevention in atrial fibrillation (AF),
unfortunatly they also increase the risk of bleeding. For this reason, physicians face
benefit-risk trade-offs when prescribing anticoagulants to AF patients. Although
the unmet medical need for safer anticoagulants has been documented, the actual
patients and physicians preferences for outcomes associated with anticoagulants
are yet to be documented. OBJECTIVES: To quantify Japanese patients and physi-
cians preferences for benefits and risks associated with the use of anticoagulants in
AF and to enable cross-patient and physician comparison.METHODS: Patients45
years old with a self-reported physician diagnosis of AF, and board-certified inter-
nists, cardiologists, neurologists and neurosurgeons currently treating AF patients
were invited to complete a web-enabled, choice-format conjoint survey that in-
cluded a series of trade-off questions. Each trade-off question included a pair of
hypothetical anticoagulants defined by therapy-induced changes in the risk of
stroke, myocardial infarction, embolism, and bleeding. In addition, respondents
were asked to revisit their anticoagulant choice based on the risk of all-cause death
and on the monitoring requirement. Patients were asked to choose anticoagulants
for themselves, while physicians chose anticoagulants for virtual patients. Ran-
dom-parameters logit was used to estimate a relative preference weight for the risk
of each event based on respondents’ choices in the trade-off questions. RESULTS:
A total of 152 patients and 164 physicians completed the survey. Overall patients
and physicians considered all-cause death to be the least desirable outcome.
Among non-fatal outcomes, patients considered the risk of disabling stroke to be
2.6 times more important than extra-cranial major bleeding and 16 times more
important than non-major clinically relevant bleeding compared to 1 time and 2.7
times for physicians. CONCLUSIONS: Japanese patients and physicians have dif-
ferent preferences for non-fatal outcomes associated with anticoagulants, with
patients willing to tolerate a greater risk of bleeding for stroke prevention than
physicians.
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Although effective for stroke prevention in atrial fibrillation (AF), anticoagulants
increase the risk of bleeding. The relative importance of benefits and risks associ-
ated with anticoagulants is influenced by various factors and has mostly been
documented only in physicians. OBJECTIVES: To identify patients characteristics
influencing the relative importance of non-fatal outcomes associated with
anticoagulants. METHODS: Data from a choice-format conjoint survey asking AF
patients to choose between hypothetical anticoagulants were used to estimate
importance weights for non-fatal outcomes associated with anticoagulants. The
influence of patients characteristics was tested by evaluating the significance of
interactions between importance weights and age, gender, prior use of anticoagu-
lants, personal history of stroke, family history of stroke and personal or family
history of bleeding. RESULTS: A total of 152 patients completed the survey. Only
two patients characteristics significantly influenced the relative importance of
non-fatal outcomes associated with anticoagulants. Overall, the least desirable
non-fatal outcome was disabling stroke. Using disabling stroke as a reference,
patients characteristics such as prior use of anticoagulants increased the relative
importance of non-disabling stroke by 48%, major extra-cranial bleeding by 12%
and non-major clinically relevant bleeding by 82%. On the other hand, personal or
family history of bleeding increased the relative importance of major extra-cranial
bleeding by 19% and non-major clinically relevant bleeding by 34% while decreas-
ing the relative importance of non-disabling stroke by 15%. CONCLUSIONS: This
study documents the impact of patients prior experience on relative importance of
non-fatal outcomes associated with anticoagulants. Proper explanation of the ben-
efits and risks of anticoagulants may play a role in patients understanding and
A380 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
acceptance of stroke prophylactic treatment. Interestingly, no single patients char-
acteristics changed the fact that AF patients were willing to accept a non-zero risks
of bleeding in exchange for prevention of disabling strokes.
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OBJECTIVES: To assess item analysis and dimensional validity of a new question-
naire developed to measure Satisfaction with medical care in patients with atrial
fibrillation, in order to accomplish item reduction. METHODS: The initial instru-
ment was composed by 37 items, arranged in 6 dimensions: 1- Efficacy (4 items), 2-
Ease and convenience (7 items), 3- Impact on daily activities (11 items), 4- Satisfac-
tion with medical care (6 items), 5- Medication undesired effects (6 items), and 6-
Overall satisfaction (4 items). Items and dimensions where extracted from review-
ing previous English instruments, 3 focus groups with chronic patients, and a panel
composed by 8 experts. Additionally 3 Visual Analog Scales (VAS) measuring Qual-
ity of Life, Effectiveness and Overall Satisfaction were applied. A convenience sam-
ple of 118 patients was used. Classic psychometric theory item analysis tech-
niques, exploratory factor and confirmatory factor analysis, test-retest and
correlation with VAS scales were used. RESULTS: The questionnaire was reduced
in length to 25 items, but the Impact dimension had to be divided in 2 dimensions:
Treatment inconvenience and Treatment Control. The reduced version presents
an overall Cronbach alpha of 0.861, with acceptable dimensional reliabilities (0.764-
0.908). Individual dimensions were well formed and correlated in different degrees,
being the dimension of Satisfaction with medical care the most independent one.
Test-retest correlations were high (0.784-0.965) and correlations with VAS scales
were meaningful. CONCLUSIONS: The 25-item questionnaire shows good reliabil-
ity and validity to assess satisfaction with medical care in patients with atrial
fibrillation. Further research is needed to examine if the questionnaire could be
generalized to different populations of patients with atrial fibrillation.
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OBJECTIVES: To describe demographical and medical characteristics of patients
treated with bi- or multi- antihypertensive therapies and to outline the link be-
tween therapeutic scheme, blood pressure control and patients co morbidities.
METHODS: A retrospective study was undertaken, based on the IMS Lifelink Elec-
tronic Medical Records database (Disease Analyzer), investigating age, gender,
blood pressure control and co morbidities according to the number and type of
associated antihypertensive therapies. RESULTS:A total of 13,618 patients, treated
by bi- or multi- antihypertensive therapies and for whom blood pressure levels
were available have been included in a 2008 study cohort (mean age  66.8, 48%
men). Respectively 39% and 58% of patients had a controlled blood pressure de-
pending on the threshold of the control (140/90 or 140/90), showing the im-
portance of the precise threshold in real-life. Respectively 1.5% and 0.3% of patients
had a blood pressure of over 160/100 and over 180/110. Significantly more patients
(p 0.05) have a controlled blood pressure under tri-therapy (41.6%/64.2% accord-
ing to the two previous thresholds) rather than under bi-therapy (37.9%/57.8%), but
no control difference is seen in patients treated by tri-therapy vs 4 or more. 59.4%
of patients have at least one cardiovascular, renal or diabetic co morbidity; a sta-
tistical link has been shown between the patient number of co morbidities and the
number of associated antihypertensive drugs in the treatment scheme.
CONCLUSIONS:The number of antihypertensive associated in a treatment scheme
increases with the patient co morbidity level. Despite the use of bi- or multi-ther-
apies, Sixty-one percent of patients who are being prescribed several antihyper-
tensive drugs do not have a controlled blood pressure (140/90); prescribing 4 or
more associated antihypertensive does not seem to increase the percentage of
controlled patients.
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OBJECTIVES: Disease definitions can evolve over time, and may be influenced by
the prevailing evidence base/understanding of the condition. Without a common
definition, significant scope exists for unanticipated impact on the health care
system and patients. We investigated this through assessment of primary non-
familial hypercholesterolaemia (PN-FH) in UK adults. METHODS: The 2007 NICE
Technology Appraisal of ezetimibe reported prevalence of PN-FH from two differ-
ent sources: 1) a 1999 publication reporting prevalence at 4.2%, based on a defini-
tion that PN-FH was “responsible for all cholesterol levels above the 95th percentile not
accounted for by a familial cause”; and 2) a 2003 article, reporting a range of 20-80%,
using a contemporary definition of PN-FH: a cholesterol level above a desirable/
recommended level, where familial and secondary causes have been excluded. We
used the older definition (4.2%) and lower bound of the range (20%) to estimate the
prevalence of PN-FH in UK adults. Simvastatin 40mg costs and Heart Protection
Study (HPS) results were used to estimate drug acquisition costs and number of
events prevented. RESULTS: At prevalence rates of 4.2% vs. 20%, 2.1m or 9.8m UK
adults have PN-FH. Accounting only for those diagnosed and requiring treatment
(30% of the population), the 1999 definition (4.2%) estimates 618,940 patients re-
quiring medication vs. 2,947,332 using the lower bound of the modern definition
(20%). The respective 5-year (mean follow-up in HPS) drug acquisition costs would
vary from £48.0m to £228.6m, and be expected to prevent 9,414 or 44,826 vascular
deaths, and 33,301 or 158,575 major vascular events (including 7,241 or 34,481
non-fatal MI’s and 8,022 or 38,201 non-fatal strokes). CONCLUSIONS: The impor-
tance of an accurate and contemporary definition of the condition under investi-
gation is paramount. Alternative rates available to NICE are associated with differ-
ences in 5-year drug cost of at least £180m, over 35,000 fewer vascular deaths and
125,000 fewer vascular events.
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OBJECTIVES: Egypt has long been trying to reform health care reimbursement
mechanisms. Currently, health care out-of-pocket expenditure in Egypt is almost
72%, with over 30% of total health care expenditure (THE) dedicated to medica-
tions1. At the same time, hypertension is becoming one of the main killers of
Egyptian adults. With an inefficient national scheme for financial protection
against chronic illnesses, anti-hypertensive medications are becoming a burden
for the Egyptian household budget. This research aims to examine factors affecting
affordability of anti-hypertensive medications in Egypt under current reimburse-
ment systems. METHODS: This research will use anti-hypertensive drugs sales
data as a proxy to identify the pattern of usage of antihypertensive drugs in differ-
ent regions of Egypt, under the different reimbursement systems (including out-
of-pocket). A trend (if any) will be drawn over time, to identify the impact of chang-
ing reimbursement policies, and the increase of medication prices on anti-
hypertensive drugs usage. For this purpose, we will look into sales/ dispensing data
from main health care providers; Ministry of Health & Population (MoHP), Health
Insurance Organization (HIO), and retail pharmacies’ sales data in the different
regions of Egypt. As well as demographic characteristics, health care services de-
livery models in each region, and the average annual income of individuals. Dif-
ferences between the different regions of Egypt, & factors affecting them, shall also
be highlighted. RESULTS: Weak and fragmented health insurance system, leads to
a high out-of-pocket drug expenditure, affecting affordability of, & subsequently
access to, anti-hypertensive medications. CONCLUSIONS: Efficient drug reim-
bursement systems should be improved to achieve better patient access to chronic
illnesses’ medication.
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OBJECTIVES: In May 2012, generic atorvastatin has become available in Belgium.
This study examines the impact of market entry of generic atorvastatin on Belgian
statin market and on cost-effectiveness of statin therapy. METHODS: Using IMS
Health data, the Belgian 2000-2011 statin market was analyzed in terms of total
expenditure, annual price of statin treatment, and number of patients. Also, a
simulation analysis projected market shares in the Belgian statin market from 2012
to 2015 following market entry of generic atorvastatin. This analysis was based on
three scenarios regarding the number of patients taking specific statins. Savings
associated with an atorvastatin price reduction of 50%-70% were calculated. A
literature review of economic evaluations was conducted to assess the cost-effec-
tiveness of generic atorvastatin. RESULTS: Statin expenditure more than doubled
from €113 million in 2000 to €285 million in 2011, mainly as a result of higher
expenditure on atorvastatin and rosuvastatin. Although the number of patients
treated with simvastatin increased by nearly 800% during 2000-2011, the resulting
increase in expenditure was partially offset by price reductions due to generic
competition and a simvastatin tender. The simulation analysis indicated that ator-
vastatin will become the dominant product in the Belgian statin market (market
share by expenditure of 47%-66% by 2015). Annual savings were projected to attain
€108.6-€153.7 million for a 50% reduction in the atorvastatin price and €152.0-€215.2
million for a 70% price reduction. The literature suggests that generic atorvastatin
is cost-effective as compared to simvastatin and becomes more cost-effective at
higher daily doses. The limited evidence about the cost-effectiveness of rosuvas-
tatin as compared with generic atorvastatin is inconclusive. CONCLUSIONS: Ge-
neric atorvastatin is cost-effective as compared to simvastatin, is projected to be-
come the dominant product in the Belgian statin market and is expected to
generate substantial savings to health care payers.
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